Moderna’s Early Data On COVID-19 Vaccine Prompts Dosing Revisions For Phase II

Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.